by Maria Zannes | Aug 1, 2018 | Press Releases
JULY 31, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin Y. Meghji, managing partner of M-III Partners L.P. (M-III), to its Board of...
by Maria Zannes | Jul 23, 2018 | Press Releases
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is...
by Maria Zannes | May 18, 2018 | Press Releases
MAY 14, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of...
by Maria Zannes | Mar 15, 2018 | Press Releases
FEBRUARY 28, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN...
by Maria Zannes | Nov 30, 2017 | Press Releases
NOVEMBER 29, 2017 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors. Dr. Squinto is a Venture Partner...
by Maria Zannes | May 3, 2017 | Press Releases
MAY 3, 2017 (SAN ANTONIO, TX ) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. The EPO patent, titled “System...
